- "Better than Nature" Garlic Product helping to maintain a healthy cardiovascular system, Study Shows By : Cardiology News
A study presented at the Annual Meeting of the American College of Nutrition shows that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic. - $7.2 Million NIH Grant To Yale For Cardiovascular Imaging By : Cardiology News
Three-dimensional diagnostic images of the heart analyzed at the bedside may be possible in the future thanks to a five-year $7.2 million National Institutes of Health (NIH) bioengineering research partnership (BRP) grant to a team of engineers, scientists and physicians at Yale University School of Medicine. - 50,000 Angioplasties Each Year Of No Benefit By : Cardiology News
Tens of thousands of angioplasty procedures carried out each year in the USA after heart attacks are not only a waste of time and resources, but they could also be dangerous for the patients, say experts after looking at 2,166 cases. - A Little Carbon Monoxide Goes A Long Way When Preventing Pre-eclampsia By : Cardiology News
Researchers have shown that carbon monoxide may prevent the placental cell death caused by oxidative stress injury, possibly averting the risks of pre-eclampsia. The report by Bainbridge et al., "Carbon monoxide inhibits hypoxia/reoxygenation-induced apoptosis and secondary necrosis in syncytiotrophoblast," appears in the September issue of The American Journal of Pathology. - A Simple, Noninvasive Test Measures Survival Time In Adult Pulmonary Hypertension By : Cardiology News
Researchers have developed a simple, noninvasive way to measure right ventricular function in the heart to predict survival of adults who suffer from pulmonary hypertension. - A World First In The Treatment Of A Young Patient With A Completely Blocked Yet Vital Heart Artery By : Cardiology News
The Sainte-Justine University Hospital Center and the Montreal Heart Institute (MHI) proudly announce the achievement of a world first in the treatment of a young pediatric patient's coronary arteries. Marie-Jeanne, an 11 ½ years old, who suffers from severe heart problems as a result of Kawasaki disease, became the first child in the world to have benefited from a new technology, called the CROSSER, which is used to treat patients with completely blocked coronary arteries. - Abbott Announces Completion Of Enrollment In Groundbreaking Vulnerable Plaque Study By : Cardiology News
Abbott today announced completion of enrollment in a landmark study designed to increase clinical understanding of "vulnerable" plaque -- a lipid-rich coronary plaque that suddenly ruptures -- believed to be the cause of most heart attacks. The study enrolled 700 acute coronary syndrome patients receiving stents in the United States and Europe. Patients will be followed up for at least two, and up to five, years. - Abbott Begins Early International Launch Of XIENCE™ Everolimus Eluting Coronary Stent System By : Cardiology News
Abbott today announced that it has begun the international launch of the XIENCE™ V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease earlier than the company's original projections. The XIENCE V stent system will be launched in the majority of European countries immediately. - Abbott Enrolls First Patient In New Clinical Trial Of XIENCE(TM) V Drug Eluting Stent By : Medical News
Abbott (NYSE: ABT) announced today enrollment of the first patient in its SPIRIT IV clinical trial for the continued evaluation of the safety and efficacy of the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in a more complex patient population. - Abbott Enrolls First Patient In New Clinical Trial Utilizing XIENCE™ V Drug Eluting Stent By : Cardiology News
Abbott announced today enrollment of the first patient in its SPIRIT IV clinical trial for the continued evaluation of the safety and efficacy of the XIENCE™ V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in a more complex patient population. - Abbott Receives FDA Clearance For I-STAT(R) BNP Test To Diagnose Congestive Heart Failure By : Medical News
Abbott (NYSE: ABT) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its i-STAT(R) BNP cartridge, a new point of care diagnostic test used to quickly assess the level of BNP (brain naturietic peptide) in patients in emergency rooms, heart failure clinics and observation units, laboratories and other critical care settings. - Abbott Reports Initial Results From World's First Clinical Trial Featuring A Fully Bioabsorbable By : Cardiology News
Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented today during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. - Abbott's XIENCE V(TM) Drug-Eluting Coronary Stent Superior To TAXUS(R) Stent In SPIRIT II Clinical By : Cardiology News
Positive six-month results of Abbott's SPIRIT II clinical trial of the XIENCE(TM) V Everolimus Eluting Coronary Stent System were presented today at the World Congress of Cardiology conference in Barcelona, Spain. - About.com Launches Podcast Series Focused on Heartburn, Acid Reflux By : Health News
About.com has launched a six-part podcast series to educate consumers on how to cope with heartburn and acid reflux disease. The series, sponsored by AstraZeneca, is featured at http://heartburnpodcast.about.com/. It will provide listeners with in-depth knowledge on topics such as: What Causes Heartburn; Acid Reflux and Your Diet; How to Talk to Your Doctor about Acid Reflux; Exercising with Acid Reflux; and How Stress Affects Your Acid Reflux. - Add Walnuts To High-fat Meals And Help To Protect Arteries Against Short-term Damage By : Cardiology News
If you've been going a little nuts trying to eat a healthier diet, you just might be on the right track. New research shows that consuming a handful of raw walnuts along with meals high in saturated fat appears to limit the ability of the harmful fat to damage arteries. - Adult Heart Cells Learn To Heal By : Cardiology News
Cells in the outermost layer of the heart can be guided by a specific protein to move deeper inside and help to repair a failing adult heart. Research published today by Nature, reveals how thymosin B4, a protein already known for its ability to reduce muscle cell loB after heart attack, can instruct the heart to heal itself. - African-Americans Have Same Risk As Pack-a-Day Smokers For Developing Peripheral Arterial Disease By : Cardiology News
September first is the kickoff day for the Legs For Life(R) free national screening program for the early detection of peripheral arterial disease (PAD) to prevent amputation, heart attack and stroke. Although 10 million Americans have PAD, African-Americans are twice as likely to develop it. Their increased risk makes them as vulnerable as someone who has smoked a pack of cigarettes a day for 20 years. - After Heart Attack Late Angioplasty No Better Than Drug Therapy By : Cardiology News
About one-third of heart attack patients do not receive treatment to open blocked arteries within the recommended 12-hour timeframe after a heart attack - All Men With ED Should Be Monitored For Heart And Vascular Disease Say Researchers By : Medical News
An Italian study of men with erectile dysfunction and coronary artery disease (CAD) has shown for the first time that the rates of dysfunction differ according to the type and severity of the disease. - Alteon's ALT-2074 Demonstrates Ability To Reduce Infarct Size By 80 Percent In Mice With Haptoglobin By : Cardiology News
Alteon Inc. (Amex: ALT) announced today that data demonstrating the ability of its compound ALT-2074 (formerly BXT-51072 licensed from OXIS International, Inc., OTC Bulletin Board: OXIS.OB), to reduce myocardial injury in mice is the subject of an abstract being presented at the American Heart Association Scientific Sessions 2006 in Chicago, IL, by a research team from the Rappaport Institute, Israel. - Altered Sodium Channel Function Linked To Heart Failure By : Cardiology News
The results of a study, using mice and heart muscle cells from rabbits, by researchers from Georg-August-University Gottingen, Germany, have provided a potential molecular explanation for the abnormally rapid heartbeats known as ventricular tachyarrhythmias (VTs) that can cause the sudden death associated with heart failure. - Always The Gentleman: CaMKII Opens The Door For Calcium To Enter By : Cardiology News
Aldosterone has recently been identified as a pathogenic stimulus of heart failure. It is produced by cells of the adrenal gland if their intracellular Ca2+ concentration is elevated, such as occurs after stimulation with angiotensin II. - Ambrisentan Data to Be Presented at World Congress of Cardiology 2006 By : Health News
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) has been selected for presentation at the World Congress of Cardiology 2006. - American College Of Cardiology Foundation's NCDR Creates Network To Measure Patient Care By : Cardiology News
The American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDRTM) announced today that it will launch a new initiative to improve safety and outcomes for patients with Acute Coronary Syndrome (ACS). This initiative will combine the data collection and quality reporting features of two leading national ACS registries to create the largest and most comprehensive national cardiovascular patient database ever developed. - American College Of Cardiology/American Heart Association/European Society Of Cardiology Scientific By : Medical News
Risk factors for stroke should be used to determine whether anti-clotting therapy is given to people with an irregular heartbeat called atrial fibrillation (AF), according to revised Guidelines for the Management of Patients with Atrial Fibrillation released today by the American College of Cardiology, American Heart Association and the European Society of Cardiology. - American Heart Association Statement On Use Of Drug-Eluting Coronary Stents By : Cardiology News
A coronary stent is a wire mesh tube used to prop open a previously blocked artery to the heart - American Heart Association Urges New Congress To Tackle Impending Baby Boomer Health Care Crisis By : Cardiology News
The American Heart Association (AHA) today urged the new congressional leadership to take proactive measures to avert a cardiovascular crisis among aging baby boomers and place increased funding for heart disease and stroke research and prevention programs high on their health care agenda. - American Heart Association Web Site Helps Caregivers Help Themselves; As Numbers Grow By : Cardiology News
A new American Heart Association Web site -- http://www.americanheart.org/caregiver -- is addressing the emotional needs of the approximately 50 million people in the United States caring for a family member or friend who has a chronic medical condition. - An Equal Opportunity Killer: Heart disease in women. By : Judah98 Friedman98
Venous ulcers are the most common found leg ulcers. Venous insufficiency is the inappropriate functioning of the one-way valves in the veins. Generally veins take blood from the feet, ankles and the lower legs to the heart. Venous disease affects the quality of life of the person infected and also the costs can be quite cumbersome. Although the pathological causes leading to this venous ulceration are unknown, a better realization of the current pathophysiology of ulceration will lead to novel approaches in its control and management. In addition to the compression therapy, latest kinds of wound dressings, surgical modalities, bioengineered tissue, topical and systemic therapeutic agents can be used. - Anti-cancer Drug Shows Early Promise In Pulmonary Hypertension By : Cardiology News
A drug used to treat kidney cancer can prevent the development of pulmonary hypertension (high blood pressure in the lungs) in rodents, report researchers from the University of Chicago at the 2006 annual meeting of the American Heart Association, Nov. 12-15 in Chicago. There is no curative therapy for this condition. - Antibody Binding To Heart Muscle Cells Disrupts The Beating Heart By : Medical News
Congenital heart block (CHB) is a condition in which the transfer of electrical nerve impulses that regulate the rhythmic pumping of heart muscle is altered. Although CHB is strongly associated with the transfer, via the placenta, from mother to fetus of antibodies to the ribonucleoproteins SSA/Ro and/or SSB/La, the precise role of these antibodies in CHB was not previously known. - Aortic Aneurysms Are Often Familial Diseases By : Cardiology News
A detailed study of 520 patients with thoracic aortic aneurysm (TAA) and dissection indicates a very strong genetic link, Yale School of Medicine researchers report in the Annals of Thoracic Surgery. - Arixtra(R) Receives Priority Review By The FDA In Acute Coronary Syndromes (ACS) By : Cardiology News
Australian drug development company Alchemia Limited (ASX: ACL) received further positive news for its Synthetic Heparin with the priority review for GlaxoSmithKline's (GSK) supplemental new drug application (sNDA) for Arixtra(R) in treating acute coronary syndromes (ACS) by the US Food and Drug Administration. - Arteriogenesis And Angiogenesis: New Tricks For BMX By : Cardiology News
The symptoms of coronary artery disease and peripheral arterial disease are caused by decreased blood flow, which is known as ischemia, to the heart muscles and/or other tissues, respectively. This in turn triggers local expansion of the lumen of blood vessels (arteriogenesis) and the growth of new blood vessels (angiogenesis), which together allow blood flow to the damaged tissue to be restored. - Assessment Of A Race-Based Pharmaceutical Drug By : Cardiology News
BiDil is the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African-Americans, in the treatment of congestive heart failure. This analysis discusses background issues to help prepare physicians to counsel patients about this controversial drug. - ATS Medical Signs Exclusive Distribution Agreement With Novare Surgical Systems, Inc. For Enclose II By : Cardiology News
ATS Medical, Inc. (Nasdaq: ATSI) -- developer, manufacturer and marketer of a wide variety of cardiac surgery products and services, today announced an exclusive distribution agreement with Novare Surgical Systems, Inc. for Novare's Enclose II(R) cardiac anastomosis assist device. ATS Medical will distribute the device in the United States, Germany, France and the United Kingdom. - AVI BioPharma Discusses Phase II Cardiovascular Clinical Study By : Health News
Clinicians involved in the performance of the APPRAISAL Phase II clinical study sponsored by AVI BioPharma, Inc. (Nasdaq: AVII) and AVI’s partner Cook Group Inc. presented promising preliminary observations at the 18th Annual Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. last week. The multi-center APPRAISAL study is designed to evaluate Resten-MPTM delivered intravenously via microparticle technology, in conjunction with placement of one or more bare-metal stents. - Battle Against Heart Disease Begins In Childhood By : Cardiology News
Heart disease is one of the leading causes of sickness and premature death in adults. - Bayer Diagnostics Expands Availability Of High Sensitivity And High Precision Troponin Assay By : Medical News
Bayer HealthCare, Diagnostics Division, a member of the Bayer Group (NYSE: BAY), announced today the availability of its new Tnl-Ultra(TM) Troponin assay on ADVIA Centaur(R) CP Immunoassay system. The launch of the TnI-Ultra assay on ADVIA Centaur CP provides additional options for high sensitivity troponin testing on Bayer's immunoassay systems. ADVIA Centaur CP TnI-Ultra assay is an addition to ADVIA Centaur and ADVIA IMS TnI-Ultra assays released earlier this year. - Benefits Of Cord Blood Banking By : Alvin Toh
If you are pregnant, you probably have received information about cord blood banking. This is an opportunity for you to bank your child’s umbilical cord blood. - Bioheart, Inc. Expands Clinical Trials Of Adult Myogenic Stem Cell Treatment For Heart Attack And Ad By : Cardiology News
Bioheart, Inc., a biotechnology company focused on the development of innovative cell therapies designed to repair areas of damaged muscle tissue in a patient's heart and improve cardiac function, is expanding its United States and European clinical trials of its MyoCell(TM) adult myogenic (muscle) stem cell composition and MyoCath(R) needle-injection catheter product candidates. - Bioheart, Inc. Expands Clinical Trials Of Adult Myogenic Stem Cell Treatment For Heart Attack And Ad By : Cardiology News
Bioheart, Inc., a biotechnology company focused on the development of innovative cell therapies designed to repair areas of damaged muscle tissue in a patient's heart and improve cardiac function, is expanding its United States and European clinical trials of its MyoCell(TM) adult myogenic (muscle) stem cell composition and MyoCath(R) needle-injection catheter product candidates. - Blood Pressure Kit: Your Doctor At Home By : Roberto Modesto
A blood pressure kit helps you keep an eye on your health and potentially saves your precious life. Read on to know more about it. - Blood Test Predicts Sickle Cell Disease Complication, Identifies Patients At High Risk Of Death By : Medical News
A team of scientists with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has found that a hormone detected in a simple blood test can identify patients with sickle cell disease who have developed a life-threatening complication called pulmonary hypertension. The team has also found that the same hormone is a clear predictor of death in adult sickle cell patients. - Boosting Protein Levels Staves Off Heart Failure, Jefferson Scientists Find By : Cardiology News
Boosting levels of a protein in the heart might help protect against the development of heart failure, particularly in those who have had heart attacks. - Boosting The ‘Good' Cholesterol, High-Density Lipoprotein (HDL) By : Medical News
When it comes to cholesterol, most of us worry about too much of the “bad” kind, low-density lipoprotein (LDL). It causes plaque to build up in and potentially block the arteries that supply your heart with blood. - Boston Globe Examines Concerns Over Heart Disease Guidelines Published In Paid Supplement To Medical By : Medical News
The Boston Globe on Tuesday examined controversy over heart disease detection guidelines published recently in a paid supplement to the American Journal of Cardiology. The guidelines recommend that all men ages 45 to 75 and women ages 55 to 75 receive screenings -- as well as follow-up tests years later -- to detect calcium deposits in blood vessels and measure blood flow to the brain. The recommendations, if followed nationwide, would affect 50 million people and cost more than $25 billion. - Boston Scientific Announces Availability Of Advanced Feature In Company's Heart Failure Devices By : Cardiology News
Boston Scientific Corporation (NYSE: BSX) today announced the launch of software enabling its Left Ventricular (LV) Offset feature in the Company's CONTAK RENEWAL(R), RENEWAL 3, and RENEWAL 3 RF cardiac resynchronization therapy defibrillators (CRT-D). LV Offset allows physicians to further fine tune synchronization of the heart by allowing adjustment of the delay between right and left ventricular pacing, which helps physicians provide more tailored care for heart failure patients. - Boston Scientific Announces Major Expansion Of Its LATITUDE(R) Patient Management System By : Cardiology News
Boston Scientific Corporation (NYSE: BSX) today announced a U.S. Food and Drug Administration (FDA) approval that permits the LATITUDE(R) Patient Management System to now be used in virtually all of the Company's implantable defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). This approval increases the number of patients eligible to receive the benefits of home monitoring by more than 150,000 in the United States. - Boston Scientific Becomes Only Company With Two Drug-eluting Stent Platforms By : Cardiology News
Boston Scientific Corporation (NYSE: BSX) has announced that the PROMUS™ everolimus-eluting coronary stent system has received CE Mark approval, making Boston Scientific the only company to offer two distinct approved drug-eluting stent (DES) platforms in the CE geographies. This approval allows Boston Scientific to begin marketing the new DES in the 25 countries of the European Union and will support market registrations in other regulated countries in Asia, Latin America and Eastern Europe. - Boston Scientific Reports Positive Results For Its Carotid Artery Stenting Trial By : Cardiology News
Boston Scientific (NYSE: BSX) today announced two-year data from its BEACH carotid artery stenting (CAS) clinical trial. The study evaluates the effectiveness of stenting with embolic protection for patients who are at high-risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease. The results were presented at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. - Boston Scientific To Highlight Broad Range Of Clinical Trial Results Reinforcing Safety And Efficacy By : Cardiology News
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 22 to 27 in Washington, D.C - Breakthrough In Preventing Sudden Cardiac Death By : Cardiology News
The physicians at Westside Medical Associates of Los Angeles (WMALA) in conjunction with Westside Medical Imaging have implemented the use of the novel and exciting Micro-T-Wave Alternans technology for identifying patients at risk for sudden cardiac death (SCD). - British Heart Foundation Announces Latest Research Investment At Surrey By : Cardiology News
The British Heart Foundation (BHF) has announced a new raft of research grants worth £5.3 million to scientists across the UK. Among those winning awards are researchers from University of Surrey. Dr Jian-Mei Li and Professor Susanna Hourani received £143,547 to investigate an abundant chemical in our bodies, called adenosine, which can cause changes in the diameter of our smallest blood vessels in tissues, which can in turn cause a change in our blood pressure. - British Heart Foundation Announces New Round Of Research Investment In Dundee By : Medical News
The British Heart Foundation (BHF) has announced a new raft of research grants worth almost £900,000 to scientists across Scotland.
Among those winning awards are researchers from the University of Dundee. - British Stoicism Means More Die Of Heart Attack By : Cardiology News
Half of all Britons will stoically try to ignore possible heart attack signs, deciding to wait a while to see whether they will go away - Bypass Surgery Tops Angioplasty For Sickest Heart Patients By : Cardiology News
Patients with severe coronary artery disease live longer if they receive coronary artery bypass surgery as their initial treatment instead of artery-opening angioplasty or heart medications, according to a Duke University Medical Center analysis. - Cambridge Heart to Present at the Rodman & Renshaw 8Th Annual Healthcare Conference By : Health News
Cambridge Heart, Inc. (OTCBB-CAMH) today announced today that its President and CEO, David A. Chazanovitz, will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 2:30 PM EST. The conference is being held November 6 to 8 at the New York Palace Hotel in New York City.
Mr. Chazanovitz will be discussing recent business highlights. The presentation will be webcast and can be accessed on http://www.wsw.com/webcast/rrshq10/camh.ob. - Can Cholesterol-Lowering Drugs Prevent Heart Disease? By : Groshan Fabiola
In the last few years, medical scientists have had divergent opinions regarding the actual efficiency of common cholesterol-lowering medications. - Carbon Monoxide Gas Is Shown To Reverse Symptoms Of Pulmonary Hypertension By : Cardiology News
In a medical case of Jekyll and Hyde, carbon monoxide - the highly toxic gas emitted from auto exhausts and faulty heating systems - has proven effective in treating the symptoms of pulmonary arterial hypertension (PAH), an extremely debilitating condition that typically leads to right heart failure and eventual death. - CardiacAssist Wins FDA Approval For TandemHeart(R) Escort Controller By : Cardiology News
CardiacAssist, Inc. has received FDA 510(k) market approval for its new TandemHeart(R) Escort(R) Controller. - Cardica Receives 510(k) Clearance For C-Port XA(TM) Distal Anastomosis System For Use In Coronary Ar By : Cardiology News
Cardica, Inc. (Nasdaq: CRDC) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its C-Port xA(TM) Distal Anastomosis System in the U.S. - Cardio Vascular Medical Researchers Share $900,000 In Funding By : Cardiology News
The work of 17 Australian scientists in the area of cardio vascular medical research were applauded in Sydney on October 21. - Cardiocerebral Resuscitation Better Than CPR For Out-Of-Hospital Cardiac Arrest By : Cardiology News
Survival rates following cardiac arrest went up 300 percent when emergency responders used Cardiocerebral Resuscitation, a new resuscitation approach for cardiac arrest pioneered at The University of Arizona Sarver Heart Center. Because the new technique does away with mouth-to-mouth breathing, it enhances the willingness to perform resuscitation in lay individuals. - CardioTech Signs Agreement With Principle Investigator For CardioPass(TM) European Clinical Trial By : Medical News
CardioTech International, Inc. (Amex: CTE), a developer and manufacturer of innovative medical devices, today reported that it has signed an agreement with a Principle Investigator for the European clinical trial of its CardioPass(TM) synthetic coronary artery bypass graft. - Cardiovascular Disease Deaths Highest In Eastern Europe, Middle East By : Cardiology News
Eastern European and Middle Eastern patients with diseased blood vessels have the highest rates of heart attacks and strokes, and the highest rates of death from those conditions, compared with similar patients in other regions of the world, according to a preliminary analysis of more than 68,000 patients in 44 countries. - Cardiovascular Disease, Sex And Gender By : Cardiology News
A team of researchers led by MUHC epidemiologist Dr. Louise Pilote announced the initial findings of the GENESIS ICE project today at the Canadian Cardiovascular Congress in Vancouver. - Cardiovascular Events Reduced By Low-Dose Aspirin By : Cardiology News
Taking low-dose aspirin daily reduces the risk of heart attack and stroke, as well as the risk of dying, among patients who previously have had a heart attack or stroke but whose cardiovascular disease has stabilized, according to a new analysis by Duke University Medical Center cardiologists. - Cardiovascular Risks May Be Reduced By Diabetes Drug By : Cardiology News
A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine. - Cardium's Generx Advances To Phase 3 Following Meeting With FDA By : Cardiology News
Cardium Therapeutics, Inc (OTC Bulletin Board: CDTP) announced that Generx(TM) (alferminogene tadenovec) is to be advanced to a Phase 3 clinical trial in women as a potential treatment for myocardial ischemia (insufficient blood flow within the heart muscle), following an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). - Carotid Artery Stenting Deemed Safe Treatment Option For Elderly In Recent Study By : Medical News
Carotid artery stenting can be performed safely in patients 80 years or older, according to study results released for the first time today at the 3rd Annual American Society of Interventional & Therapeutic Neuroradiology (ASITN) Course & Workshops in Rio Grande, Puerto Rico. - Carotid Stenting Reduces Symptoms Of Depression By : Medical News
Inserting a stent to open a narrowed carotid artery has been found to reduce symptoms of depression that may be associated with carotid stenosis, according to a study in the August issue of Radiology. - Carotid Stenting: An Open Question By : Cardiology News
Recent controversy over carotid stenting addressed by top interventionalists at TCT 2006 press conference - Cause Of Exercise Intolerance In Heart Failure Patients Explored By Study By : Cardiology News
A new study shows that blood flow to the legs is relatively normal in people with diastolic heart failure, suggesting other potential causes of their inability to do everyday activities, according to researchers at Wake Forest University Baptist Medical Center. - Chinese Medicine Meets Finnish Health Care Technology By : Cardiology News
China attracts interest all over the world. Finns are now exporting their health care expertise to China. A Chinese-Finnish collaboration, the Healthy China project is about the prevention of lifestyle diseases such as adult onset diabetes and cardiovascular diseases. - Chocoholics Teach Science A Sweet Lesson By : Cardiology News
Some "chocoholics" who just couldn't give up their favorite treat to comply with a study to test blood stickiness have inadvertently done their fellow chocolate lovers - and science - a big favor. - Cholesterol and the Risk of Heart Disease By : Groshan Fabiola
Most people are unaware of the fact that having abnormal blood cholesterol levels seriously jeopardizes one’s health. High blood cholesterol is a major cause of heart disease, rendering people very susceptible to suffering heart attack. - Cleveland Clinic-Led Study Shows Self-Administered Blood Thinners Are Safe For Atrial Fibrilation By : Cardiology News
The use of self-administered blood thinners in patients undergoing treatment for atrial fibrillation is as safe as administering anticoagulants intravenously and may result in better outcomes, including shorter hospital stays and improved heart rhythm five weeks after treatment. These are the findings of a Cleveland Clinic-led study that will be published in the Nov. 28th issue of the European Heart Journal. - Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits By : Cardiology News
Eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3, according to the results of a clinical trial published this month in Food Research International. - CoGenesys Initiates Phase 1-2 Clinical Trial Of Cardeva In Patients With Heart Failure By : Cardiology News
CoGenesys, Inc. announced today the first patient dosing in the Phase 1-2 clinical trial of Cardeva(TM), a long-acting form of B-type natriuretic peptide (BNP) that is being developed for the treatment of patients with heart failure (HF). Cardeva is the most advanced compound in CoGenesys' broad pipeline of improved, long-acting biopharmaceuticals being developed to address unmet medical needs across a spectrum of therapeutic areas. - Columbia Scientists Presented Research Findings At AHA Scientific Sessions By : Cardiology News
Columbia University Medical Center scientists presented the latest research findings in a wide range of cardiovascular areas at the 2006 American Heart Association Scientific Sessions in Chicago, Nov.12-15. Columbia's groundbreaking medical research presentations at AHA this year included: - Combination Of Personality Traits Increases Risk For Heart Disease By : Cardiology News
Frequent bouts of depression, anxiety, hostility and anger are known to increase a person's risk for developing coronary heart disease, but a combination of these "negative" personality traits may put people at especially serious risk, according to a study by researchers at Duke University Medical Center. - Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug By : Cardiology News
Studies of a rare genetic condition that increases cancer risk have unveiled a potential treatment for metabolic syndrome, a common disorder that afflicts as many as one in every four American adults and puts them at sharply increased risk of type 2 diabetes and clogged arteries. - Contact: Dr. Thomas Schlake
By : Cardiology News
The scientific evidence is strong enough to justify using folic acid as a cheap and simple way of reducing heart disease and strokes, say researchers in this week's BMJ. - Cordis STEER-IT™ Deflecting Tip Guidewire Now Available In The USA, Europe And Canada By : Cardiology News
Cordis Corporation announced today its STEER-IT™ Deflecting Tip Guidewire is now available for commercial use in the United States, Canada and Europe. The innovative product will be available in other parts of the world soon. - CV Therapeutics Completes MERLIN TIMI-36 Study By : Cardiology News
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the MERLIN TIMI-36 study of ranolazine will proceed to the study close-out phase, followed by unblinding and analysis of the data, now that the required number of endpoints have accumulated. - CVD Patients Should Be Tested For Chronic Kidney Disease By : Medical News
Cardiovascular disease (CVD) patients and those at risk for CVD should consider getting blood and urine tests that can detect chronic kidney disease (CKD), according to a new American Heart Association Science Advisory. - Cypher® Sirolimus-Eluting Coronary Stent Outperformed Taxus Stent In Long Coronary Lesions By : Cardiology News
Results from a multicenter, prospective, randomized clinical trial indicate that the CYPHER® Stent performed better than the Taxus Stent in procedures involving long coronary lesions, which are considered some of the most complex blockages to treat with balloon angioplasty. The final results from the LONG-DES-II Study were presented here today during a Late Breaking Clinical Trial Plenary Session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference. - Cytokinetics Announces Initiation Of Phase I Clinical Trial For Oral Administration Of CK-1827452 By : Cardiology News
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the initiation of a Phase I clinical trial evaluating the pharmacokinetic profile of CK-1827452 when administered orally to healthy volunteers. CK-1827452 is a direct cardiac myosin activator under evaluation as a potential treatment for patients with acute and chronic heart failure. - Cytokinetics Announces Oral Bioavailability Results For CK-1827452 By : Cardiology News
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the results from an oral bioavailability study evaluating CK-1827452 - Data In Complex Patients And Lesions From OLYMPIA Registry Support Safety And Efficacy Of TAXUS(R) By : Cardiology News
Boston Scientific Corporation (NYSE: BSX) today announced positive results from its global TAXUS OLYMPIA registry, supporting the safety and efficacy of the TAXUS(R) Liberte(TM) coronary stent system in real-world patients. The results were announced at the Cardiovascular Research Foundation's (CRF) eighteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, in Washington, D.C. - Data Presented To FDA Panel Show TAXUS Drug-Eluting Stents As Safe As Bare-Metal Stents And Far By : Cardiology News
Boston Scientific Corporation (NYSE: BSX) today presented data on its long- term randomized clinical trials to a special U.S. Food and Drug Administration (FDA) panel, showing that the TAXUS(R) paclitaxel-eluting coronary stent is as safe as bare-metal stents and far more effective in keeping arteries open and reducing the need for repeat procedures. - Data Suggest Different Outcomes Between The CYPHER(R) Sirolimus-Eluting Coronary Stent And The Taxus By : Cardiology News
The CYPHER(R) Stent outperformed the Taxus Stent in small coronary vessels and every-day medical practice in two studies published in this week's edition of the Journal of the American College of Cardiology. The results of one of the studies were reviewed in an accompanying editorial. - Data Suggest The Cypher® Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits By : Cardiology News
At four years, the CYPHER Sirolimus-eluting Coronary Stent continues to provide long-term clinical benefits (safety and efficacy) compared to bare-metal stents in patients with coronary artery disease. These data from the E-SIRIUS trial were reported here today at the World Congress of Cardiology. The E-SIRIUS trial is one of the longest-running European studies comparing the safety and efficacy of a drug-eluting stent to a bare-metal stent. - Decreased Risk Of Complications Following Bypass Surgery When Pre-Operative Breathing Training Given By : Cardiology News
Patients at high-risk of developing pulmonary complications such as pneumonia following coronary artery bypass graft surgery can reduce their risk through breathing exercises and respiratory muscle training before the operation, according to a study in the October 18 issue of JAMA. - Determining The State Of The Human Arterial System By : Cardiology News
Engineer Fernando Silvio Nuno Almirantearena has developed a system to determine the state of the human arterial system by diffuse logic techniques. This method, that can help in the prevention of heart attack, brain stroke or high blood pressure, is outlined in his PhD thesis, Inferences for diagnosis of the state of the human arterial system using elements of diffuse logic. - Developing New Biomaterials To Recruit Endothelial Cells To The Inner Surfaces Of Vascular Grafts By : Cardiology News
Biomedical engineers at Washington University in St. Louis have developed new biomaterials to recruit endothelial cells to the inner surfaces of vascular grafts. Endothelial cells normally line blood vessels and actively protect against blood clotting. Blood clotting on artificial materials is currently so severe that the use of vascular grafts is limited to large diameter vessels. - Digitalis Safe In Patients With Common Form Of Heart Failure, Study Shows By : Medical News
Despite a widely held belief that the heart drug digitalis shouldn't be given to patients with diastolic heart failure, a new analysis shows it is relatively safe. - Do Large-scale Interventions To Reduce Multiple Cardiac Risk Factors Really Work? By : Cardiology News
Coronary heart disease is a leading killer in the United States and there has been a big push to get people to lower their risk. But a new review casts doubt on whether large-scale interventions to reduce multiple cardiac risk factors really work. - Do You Want to Know Antidote to Depression? By : Vanshika Anand
Today we are living in highly competitive world. We dream to have everything big. Big house, big car, big bank balance, big friendly circle and so on.
|
